Sunitinib
Small molecule targets CSF1R, FLT1, FLT3, FLT4, KDR, KIT, MET, PDGFRA, PDGFRB, RET via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | SUTENT | — | 2007-02-02 – 2021-08-30 | fda.gov ↗ |
| Approved | EU (EMA) | Sutent | — | 2006-07-19 | europa.eu ↗ |
| Approved | US (FDA) | SUTENT | — | 2006-01-26 | fda.gov ↗ |
Trials 365 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT00583063 | Oct 2007 → Apr 2008 | cancer | University of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT00864864 | May 2007 → May 2011 | brain neoplasm, glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 167 trials | ||||||
| Phase 1 | NCT05687123 | Aug 2024 → Dec 2026 expected | pancreatic neuroendocrine tumor | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT05245968 | Dec 2021 → Dec 2026 expected | gastrointestinal stromal tumor | Taiho Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT03900793 | Aug 2019 → Aug 2027 expected | osteosarcoma | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT03905889 | Jun 2019 → Mar 2022 | renal cell carcinoma | Brown University | Terminated | No outcome recorded |
| Phase 1 | NCT03249740 | Aug 2017 → Sep 2018 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 1 | NCT02779283 | Jan 2016 → Apr 2018 | acute lymphoblastic leukemia, acute myeloid leukemia | OHSU Knight Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02483247 | Sep 2015 → May 2019 | cancer | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02386111 | May 2015 → Aug 2017 | clear cell renal carcinoma | Celldex Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT02164240 | Jul 2014 → Dec 2016 | gastrointestinal stromal tumor | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT02074878 | Jun 2014 → May 2017 | breast cancer | Mothaffar Rimawi | Terminated | No outcome recorded |
| Phase 1 | NCT02058901 | Jul 2013 → Jun 2019 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 1 | NCT01472081 | Feb 2012 → Feb 2016 | clear cell renal carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT01498835 | Feb 2012 → Nov 2014 | soft tissue sarcoma | Heidelberg University | Completed | No outcome recorded |
| Phase 1 | NCT01441388 | Dec 2011 → Nov 2013 | glioblastoma, hepatocellular carcinoma, renal cell carcinoma | Pfizer | Withdrawn | No outcome recorded |
| Phase 1 | NCT01286896 | Apr → Dec 2011 | cancer | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT01308034 | Mar 2011 → May 2016 | sarcoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1 | NCT01243359 | Oct 2010 → Feb 2014 | cancer of unknown primary site, clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01122615 | May 2010 → Jul 2014 | renal cell carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00813423 | Feb 2010 → Jul 2023 | neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01061411 | Feb 2010 → Oct 2015 | clear cell sarcoma of kidney, renal cell carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00890747 | Aug 2009 → May 2011 | Burkitt lymphoma, HIV infectious disease, HIV-associated cancer, Hodgkins lymphoma +47 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00981890 | Jul 2009 → May 2014 | metastatic malignant neoplasm in the brain | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT01005472 | Dec 2008 → Jan 2018 | metastatic melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00777478 | Dec 2008 → May 2012 | colorectal cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 1 | NCT00904657 | Oct 2008 → Apr 2009 | hypertensive disorder | University of Cologne | Completed | No outcome recorded |
| Phase 1 | NCT00747305 | Oct 2008 → Jul 2014 | kidney cancer | Harry Drabkin | Terminated | No outcome recorded |
| Phase 1 | NCT00788060 | Oct 2008 → Dec 2012 | renal cell carcinoma | Daniel George, MD | Completed | No outcome recorded |
| Phase 1 | NCT00729833 | Sep 2008 → Aug 2011 | cancer of unknown primary site | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT00555672 | Aug 2008 → Dec 2009 | gastric cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00732992 | Aug 2008 → Nov 2009 | cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00906360 | Jul 2008 → Sep 2012 | hypopharynx squamous cell carcinoma, larynx verrucous carcinoma, metastatic squamous cell carcinoma, nasal cavity and paranasal sinus squamous cell carcinoma +5 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00555620 | May 2008 → Aug 2010 | gastric cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00611728 | Mar 2008 → Jun 2010 | glioblastoma | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT00720148 | Feb 2008 → Jul 2010 | cancer | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT00520533 | Feb 2008 → Jul 2011 | renal cell carcinoma | Ludwig Institute for Cancer Research | Terminated | No outcome recorded |
| Phase 1 | NCT00631527 | Feb 2008 → Jan 2015 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00631410 | Jan 2008 → Jul 2009 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00555256 | Nov 2007 → Feb 2010 | non-small cell lung carcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00553696 | Nov 2007 → Jul 2009 | gastric neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00543504 | Oct 2007 → Apr 2020 | cancer of unknown primary site | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00694096 | Sep 2007 → Sep 2014 | renal cell carcinoma | University of Utah | Completed | No outcome recorded |
| Phase 1 | NCT00581789 | Aug 2007 → Feb 2010 | non-small cell lung carcinoma | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 1 | NCT00573404 | Jul 2007 → Sep 2009 | gastrointestinal stromal tumor | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00495872 | Jun 2007 → Oct 2012 | cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00499135 | May 2007 → May 2014 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00524186 | May 2007 → Aug 2013 | esophageal cancer, gastric cancer | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT00462553 | Mar 2007 → Jun 2010 | cancer of unknown primary site, pancreatic adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00437372 | Mar 2007 → Dec 2010 | head and neck cancer, nervous system neoplasm, thoracic cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT00372424 | Dec 2006 → Sep 2011 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00372853 | Nov 2006 → May 2010 | renal cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00528619 | Nov 2006 → Apr 2010 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00399152 | Oct 2006 → Dec 2008 | gastrointestinal stromal tumor, kidney cancer | AEterna Zentaris | Completed | No outcome recorded |
| Phase 1 | NCT00422344 | Oct 2006 → Feb 2010 | renal cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00387920 | Oct 2006 → Sep 2012 | central nervous system teratoma, childhood central nervous system germinoma, childhood central nervous system mixed germ cell tumor, pediatric CNS choriocarcinoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00291577 | Jul 2006 → Oct 2008 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00790595 | Jun 2006 → Jul 2009 | prostate cancer | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00357318 | Jun 2006 → Jul 2012 | cancer of unknown primary site | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00421512 | Mar 2006 → May 2008 | renal cell carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00402415 | Feb 2006 → Jul 2008 | neoplasm | Yale University | Terminated | No outcome recorded |
| Phase 1 | NCT00861419 | Dec 2005 → ? | cancer | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT00511849 | Nov 2005 → Feb 2009 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00599924 | Sep 2005 → Nov 2008 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00174434 | Sep 2005 → Aug 2007 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00618124 | May 2005 → Jul 2008 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00615446 | Mar 2005 → May 2009 | cancer | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00712504 | Jul 2004 → Nov 2007 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 1/230 trials | ||||||
| Phase 1/2 | NCT06222593 | Oct 2024 → Jul 2026 overdue | renal cell carcinoma | State University of New York at Buffalo | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05024214 | Nov 2021 → Dec 2026 expected | hepatocellular carcinoma, non-small cell lung carcinoma, renal cell carcinoma | 3D Medicines (Sichuan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06940349 | Oct 2021 → Jan 2026 overdue | refractory malignant neoplasm | Rabin Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03277924 | May 2017 → Jun 2024 | bone sarcoma, soft tissue sarcoma | Spanish Group for Research in Sarcomas | Completed | No outcome recorded |
| Phase 1/2 | NCT02380625 | Apr 2015 → Jan 2016 | Ebola hemorrhagic fever | Clinical Research Management, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02401815 | Mar 2015 → May 2020 | gastrointestinal stromal tumor | Cogent Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02919371 | Dec 2014 → Dec 2020 | renal cell carcinoma | King Faisal Specialist Hospital & Research Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT00905021 | Mar 2010 → Jan 2011 | breast cancer | Baylor Breast Care Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00975806 | Sep 2009 → Oct 2011 | renal cell carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00879619 | Jul 2009 → Oct 2011 | prostate adenocarcinoma | John P. Fruehauf | Terminated | No outcome recorded |
| Phase 1/2 | NCT00887575 | Jun 2009 → Jul 2013 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT01070706 | Mar → Dec 2009 | breast cancer | Jungsil Ro | Completed | No outcome recorded |
| Phase 1/2 | NCT00931450 | Mar 2009 → Oct 2011 | breast cancer | Catalan Institute of Oncology | Unknown | No outcome recorded |
| Phase 1/2 | NCT00818350 | Jan → Aug 2009 | urinary bladder neoplasm | Campania Younger Oncologists Association | Unknown | No outcome recorded |
| Phase 1/2 | NCT00753727 | Sep 2008 → Mar 2012 | soft tissue sarcoma | Australasian Sarcoma Study Group | Unknown | No outcome recorded |
| Phase 1/2 | NCT00783653 | Aug 2008 → Jul 2013 | acute myeloid leukemia | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| Phase 1/2 | NCT00891475 | May 2008 → Jan 2010 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 1/2 | NCT00673816 | May 2008 → Feb 2011 | von Hippel-Lindau disease | National Eye Institute (NEI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00417885 | Jun 2007 → Jul 2009 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT00522249 | May 2007 → May 2008 | renal cell carcinoma | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00453154 | Mar 2007 → Jun 2013 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00417677 | Mar → May 2007 | renal cell carcinoma | Wyeth is now a wholly owned subsidiary of Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT00463060 | Jan 2007 → Jul 2014 | cancer | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 1/2 | NCT00496223 | Sep 2006 → Jun 2007 | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00361244 | Jul 2006 → Oct 2007 | colorectal carcinoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00616122 | Mar 2006 → Mar 2011 | breast cancer | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 1/2 | NCT00304200 | Mar 2006 → Oct 2007 | metastatic melanoma | Northern California Melanoma Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT00137436 | Oct 2005 → May 2008 | prostate neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00457743 | Jan 2005 → Aug 2008 | gastrointestinal stromal tumor | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00113529 | Oct 2004 → Sep 2007 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 2218 trials | ||||||
| Phase 2 | NCT07667751 | Jun 2026 → Dec 2027 expected | ovarian cancer | Bai-Rong Xia | Recruiting | No outcome recorded |
| Phase 2 | NCT07477457 | Mar 2026 → Mar 2028 expected | metastatic neoplasm, osteosarcoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06208748 | Aug 2024 → Jun 2026 overdue | gastrointestinal stromal tumor | Sarcoma Alliance for Research through Collaboration | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05366816 | Oct 2023 → Dec 2026 expected | gastrointestinal stromal tumor | University of Miami | Recruiting | No outcome recorded |
| Phase 2 | NCT04644432 | Mar 2020 → Sep 2022 | renal cell carcinoma | Herlev and Gentofte Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03953079 | Sep 2019 → Dec 2020 | wet macular degeneration | Graybug Vision | Completed | No outcome recorded |
| Phase 2 | NCT04085341 | Sep 2019 → Jun 2020 | diabetic macular edema, retinal vein occlusion | Graybug Vision | Completed | No outcome recorded |
| Phase 2 | NCT03899155 | Aug 2019 → Aug 2029 expected | cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 2 | NCT03641326 | Feb 2019 → Apr 2021 | central nervous system sarcoma, gliosarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03323710 | Sep 2018 → Dec 2019 | renal cell carcinoma | Military Institute od Medicine National Research Institute | Withdrawn | No outcome recorded |
| Show all 218 trials opens the full record — a long page | ||||||
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03909724 | Oct 2019 → Jul 2021 | colorectal cancer, metastatic neoplasm | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 2/3 | NCT03025893 | Aug 2018 → Jan 2022 | adult glioblastoma, brain glioma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 2/3 | NCT01164202 | Jul 2010 → Jul 2017 | liver cancer | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT05208047 | Apr 2022 → Sep 2025 overdue | gastrointestinal stromal tumor, metastatic malignant neoplasm | Cogent Biosciences, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT02535351 | Nov 2015 → Sep 2018 | clear cell renal carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Terminated | No outcome recorded |
| Phase 3 | NCT01064310 | May 2010 → Oct 2011 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01099423 | Apr 2010 → Apr 2016 | kidney cancer | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3 | NCT00699374 | Jul 2008 → Dec 2011 | hepatocellular carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00676650 | Jul 2008 → Dec 2011 | prostate cancer | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00693992 | Jun 2008 → Nov 2013 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00375674 | Aug 2007 → Apr 2016 | kidney neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00457392 | Jul 2007 → Jul 2010 | non-small cell lung carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00457691 | Jun 2007 → Mar 2010 | colorectal cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00428597 | Jun 2007 → Apr 2009 | pancreatic endocrine carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00372567 | Jun 2007 → Nov 2009 | gastrointestinal stromal tumor | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00393939 | Feb 2007 → Feb 2010 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00435409 | Feb 2007 → Dec 2009 | breast cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00373113 | Nov 2006 → Oct 2009 | breast cancer | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00373256 | Nov 2006 → Jun 2009 | breast neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00326898 | Apr 2006 → Aug 2015 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00083889 | Aug 2004 → Sep 2008 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT02691793 | Nov 2017 → Aug 2019 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02570789 | Dec 2012 → Dec 2018 | clear cell renal carcinoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 4 | NCT01525550 | Jun 2012 → Mar 2016 | pancreatic neuroendocrine tumor | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01402089 | Jan 2012 → Jul 2015 | gastrointestinal stromal tumor, non-small cell lung carcinoma, renal cell carcinoma | Markus Joerger | Completed | No outcome recorded |
| Phase 4 | NCT00930345 | Dec 2008 → Oct 2013 | renal cell carcinoma | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT00793871 | Nov 2008 → Apr 2014 | gastrointestinal stromal tumor | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00706706 | Jul 2008 → Aug 2011 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT06032728 | Oct 2023 → Oct 2033 expected | clear cell renal carcinoma | First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT02688491 | Jul 2016 → Jul 2026 overdue | kidney cancer | First Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| — | NCT02450123 | Mar 2016 → Aug 2019 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT02551718 | Sep 2015 → Jun 2020 | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia | University of Washington | Completed | No outcome recorded |
| — | NCT02239952 | Nov 2014 → Nov 2021 | malignant glioma | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| — | NCT02013089 | Dec 2013 → May 2017 | digestive system cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT01740154 | Sep 2012 → Mar 2014 | renal cell carcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| — | NCT01636908 | Aug 2011 → Jan 2018 | cancer | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| — | NCT01190241 | Aug 2010 → Dec 2017 | cancer, metastatic neoplasm | Amsterdam UMC, location VUmc | Terminated | No outcome recorded |
| — | NCT01054911 | Oct 2009 → Sep 2014 | neoplasm | University of Alabama at Birmingham | Terminated | No outcome recorded |
| — | NCT00943839 | Feb 2009 → Nov 2014 | kidney cancer | Centre Antoine Lacassagne | Completed | No outcome recorded |
| — | NCT00656669 | Apr 2008 → Sep 2010 | breast cancer | Indiana University | Completed | No outcome recorded |
| — | NCT00849186 | Aug 2007 → Jul 2009 | kidney cancer | Roswell Park Cancer Institute | Completed | No outcome recorded |
| — | NCT00428220 | Jul 2007 → Aug 2014 | breast cancer, gastric cancer, gastrointestinal stromal tumor, hepatocellular carcinoma +6 | Pfizer | Completed | No outcome recorded |
| — | NCT00531544 | Feb 2007 → Jun 2012 | renal cell carcinoma | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT00443534 | May 2006 → Dec 2011 | neoplasm | Pfizer | Completed | No outcome recorded |
| — | NCT00798889 | Mar 2004 → Dec 2011 | cancer | Pfizer | Completed | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT00130897 | Jul 2005 → Nov 2011 | renal cell carcinoma | Pfizer | Approved for marketing | No outcome recorded |
| — | NCT00094029 | Sep 2004 → Oct 2011 | digestive system neoplasm | Pfizer | Approved for marketing | No outcome recorded |
| — | NCT06948955 | — | gastrointestinal stromal tumor | Cogent Biosciences, Inc. | Available | No outcome recorded |
Also used as a comparator or background therapy in 78 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03275558 Comparator | Jul 2018 | gliosarcoma | Center Trials & Treatment | Withdrawn | No outcome recorded |
| Phase 1 | NCT01548170 Comparator | Apr → Jul 2011 | cancer | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Completed | No outcome recorded |
| Phase 1 | NCT00884676 Background | Nov 2008 → Nov 2013 | cancer of unknown primary site | Jaime Merchan | Completed | No outcome recorded |
| Phase 1 | NCT01258348 Background | Jul 2008 → Feb 2012 | renal cell carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01743300 Comparator | Jul 2007 → Dec 2010 | — | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00705874 Background | May 2006 → Aug 2011 | cancer | Progen Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02446795 Background | Nov 2016 → Dec 2017 | renal cell carcinoma | Consorzio Oncotech | Unknown | No outcome recorded |
| Phase 231 trials | ||||||
| Phase 2 | NCT06326190 Comparator | Mar 2025 → Apr 2027 expected | meningioma | European Organisation for Research and Treatment of Cancer - EORTC | Recruiting | No outcome recorded |
| Phase 2 | NCT06427057 Background | Jul 2024 → Dec 2025 overdue | urinary system neoplasm | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05773274 Comparator | Jan 2024 → Apr 2029 expected | digestive system neuroendocrine tumor, grade 1/2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04633122 Comparator | Nov 2020 → Jul 2022 | gastrointestinal stromal tumor | Zai Lab (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02959554 Comparator | Dec 2016 → Aug 2020 | renal cell carcinoma | AIO-Studien-gGmbH | Terminated | No outcome recorded |
| Phase 2 | NCT03379012 Background | Feb 2016 → Jan 2018 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2 | NCT02230176 Comparator | Feb 2015 → Apr 2024 | pancreatic endocrine carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 2 | NCT02187302 Comparator | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01984242 Comparator | Jan 2014 → Oct 2016 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02072031 Comparator | Dec 2013 → Dec 2016 | renal cell carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01835158 Comparator | Jul 2013 → Apr 2016 | clear cell renal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01616186 Comparator | Jul 2012 → Dec 2015 | metastatic malignant neoplasm | Andrea Harzstark | Withdrawn | No outcome recorded |
| Phase 2 | NCT01673386 Comparator | Jul 2012 → Jan 2014 | renal cell carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01396408 Comparator | Feb 2012 → Jul 2015 overdue | — | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01829841 Comparator | May 2011 → Apr 2013 | renal cell carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01306045 Comparator | Feb 2011 → Feb 2014 | non-small cell lung carcinoma, small cell lung carcinoma, thymic carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01216371 Comparator | Oct 2010 → Oct 2015 | renal cell carcinoma | Association of Urologic Oncology (AUO) | Unknown | No outcome recorded |
| Phase 2 | NCT01108445 Comparator | Sep 2010 → Feb 2015 | renal cell carcinoma | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT01185366 Comparator | Aug 2010 → Sep 2019 | kidney cancer | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT01147822 Comparator | May 2010 → May 2012 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01024920 Comparator | Dec 2009 → Nov 2011 | renal cell carcinoma | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 2 | NCT00556205 Comparator | Sep 2009 | renal cell carcinoma | Massachusetts General Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT00982657 Comparator | Sep 2009 → Mar 2014 | cancer | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01082809 Comparator | Mar 2009 → Jan 2012 | adenocarcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01506336 Comparator | Oct 2008 → Sep 2011 | gastrointestinal stromal tumor | AB Science | Completed | No outcome recorded |
| Phase 2 | NCT00709995 Background | Jun 2008 → Feb 2010 | renal cell carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00578526 Comparator | Apr 2008 → Jul 2014 | urinary bladder cancer, urothelial carcinoma | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 2 | NCT00619268 Comparator | Feb 2008 → Feb 2012 | renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT00678119 Background | Jan 2008 → May 2012 | renal cell carcinoma | Argos Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT00491738 Background | Aug 2007 → Jan 2008 | renal cell carcinoma | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00393796 Comparator | May 2006 → Dec 2011 | urinary bladder cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07218926 Comparator | Dec 2025 → May 2028 expected | gastrointestinal stromal tumor | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07165418 Comparator | Sep 2025 → Dec 2028 expected | renal cell carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06726421 Background | Sep 2024 → Sep 2030 expected | renal cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05734105 Comparator | Dec 2023 → Dec 2027 expected | gastrointestinal stromal tumor | Deciphera Pharmaceuticals, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05678673 Comparator | Jan 2023 → Jul 2025 overdue | renal cell adenocarcinoma | Exelixis | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05477576 Comparator | Mar 2022 → Dec 2026 expected | carcinoid tumor, pancreatic neuroendocrine tumor | RayzeBio, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05043090 Comparator | Oct 2021 → Dec 2025 overdue | papillary renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04409223 Comparator | Sep 2020 → Mar 2022 | gastrointestinal stromal tumor | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04523272 Comparator | Aug 2020 → Jun 2025 overdue | kidney cancer | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04394975 Comparator | Aug 2020 → Apr 2024 | renal cell adenocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03768063 Comparator | Feb 2019 → Jul 2028 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03673501 Comparator | Feb 2019 → Sep 2021 overdue | gastrointestinal stromal tumor | Deciphera Pharmaceuticals, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03729245 Comparator | Dec 2018 → Jan 2022 | renal cell carcinoma | Nektar Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT03260894 Comparator | Dec 2017 → Aug 2018 | renal cell carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03091192 Comparator | Jul 2017 → Aug 2019 overdue | renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03141177 Comparator | Jul 2017 → Feb 2020 overdue | renal cell carcinoma | Bristol-Myers Squibb | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02811861 Comparator | Oct 2016 → Aug 2020 overdue | renal cell carcinoma | Eisai Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02853331 Comparator | Sep 2016 → Oct 2018 | renal cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02684006 Comparator | Mar 2016 → Aug 2023 | renal cell carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02420821 Comparator | May 2015 → Feb 2020 | renal cell carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02231749 Comparator | Oct 2014 → Jun 2017 | renal cell carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01582672 Comparator | Nov 2012 → Apr 2018 | renal cell carcinoma | Argos Therapeutics | Terminated | No outcome recorded |
| Phase 3 | NCT01694277 Comparator | Apr 2012 → Dec 2020 | gastrointestinal stromal tumor | AB Science | Completed | No outcome recorded |
| Phase 3 | NCT01265901 Background | Dec 2010 → Jul 2015 | renal cell carcinoma | Immatics Biotechnologies GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01481870 Comparator | Jan 2010 → Jul 2013 | renal cell carcinoma | Yamagata University | Unknown | No outcome recorded |
| Phase 3 | NCT00732914 Comparator | Jan 2009 → Oct 2013 | renal cell carcinoma | Sponsor GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00720941 Comparator | Aug 2008 → May 2012 | renal cell carcinoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00471328 Background | Mar 2007 → Aug 2008 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00397345 Background | Sep 2006 → Dec 2009 | clear cell renal carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 3 | NCT00075218 Comparator | Dec 2003 → May 2008 | gastrointestinal stromal tumor | Pfizer | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05949424 Comparator | May 2024 → Mar 2025 | breast carcinoma, endometrial carcinoma, ovarian carcinoma, renal cell carcinoma +1 | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT02555748 Comparator | Nov 2015 → Jan 2020 | renal cell carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT05751733 Comparator | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| — | NCT05816642 Comparator | Aug 2022 → Dec 2023 | renal cell carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03862768 Comparator | Jul 2019 → Jun 2021 | gastrointestinal stromal tumor | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT03571438 Comparator | Oct 2017 → Sep 2022 | kidney cancer | University Hospital, Grenoble | Unknown | No outcome recorded |
| — | NCT02208583 Comparator | Jun 2014 → Dec 2016 | hormone-resistant prostate carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| — | NCT02208128 Comparator | May 2014 → Feb 2018 | renal cell carcinoma | Heidelberg University | Unknown | No outcome recorded |
| — | NCT01502228 Background | Oct 2011 → Feb 2014 | renal cell carcinoma | Indiana University | Terminated | No outcome recorded |
| — | NCT00537056 Background | Oct 2007 → Oct 2011 | renal cell carcinoma | Stanford University | Completed | No outcome recorded |
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-08 | Ipsen | New data from pivotal Phase III CheckMate -9ER trial of Cabometyx® in combination with Opdivo® showed significantly improved QoL benefits and sustained superior efficacy versus sunitinib in patients living with aRCC ipsen.com ↗ |
| 2018-02-23 | Pfizer | Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma pfizer.com ↗ |
| 2017-11-16 | Pfizer | Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma pfizer.com ↗ |
| 2017-09-19 | Pfizer | Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT® in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery pfizer.com ↗ |
| 2017-05-31 | Pfizer | Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery pfizer.com ↗ |
| 2016-10-09 | Pfizer | First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal pfizer.com ↗ |
| 2016-07-08 | Pfizer | Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma pfizer.com ↗ |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 447 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sunitinib | “Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC...” NCT01176799 ↗403“This trial will be conducted to assess the activity of Sunitinib in patients affected by advanced or recurrent B3 thymoma or thymic carcinoma progressing after at least one...” NCT03449173 ↗ “In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026 “Participants with PDGFRA gene mutations will receive a drug called sunitinib, which inhibits some proteins that are thought to be key factors in the development and progression...” NCT02208583 ↗ “A Phase I Dose Escalation Study With Sunitinib (SutentR) in Combination With Capecitabine and Irinotecan (Capiri) in Previously Treated Patients With Advanced Colorectal Cancer” NCT00777478 ↗ “Sunitinib (SUTENT) is a potent tyrosine kinase inhibitor, with double antiangiogenic and antitumor activity, targeting multiple receptors as VEGF-R, PDGF-R, KIT and FLT3.” NCT01215565 ↗ “Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity” NCT00265317 ↗ “Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017 “Immediate CN followed by sunitinib therapy vs treatment with 3 cycles of sunitinib followed by CN in the absence of progression followed by sunitinib therapy.” PMID 30543350 ↗ Feb 2019 “Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.” PMID 32034074 ↗ Feb 2020 “Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.” PMID 17046465 ↗ Oct 2006 “Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT01089088 ↗ “Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.” PMID 25641662 ↗ Jan 2015 “Sunitinib is a new molecule in the family of tyrosine kinase inhibitors targeting multiple receptors which VEGFR, KIT, PDGF-R, FLT3 and RET.” NCT01215578 ↗ “Patients will receive AK104 (10mg/kg ,Q3W，intravenously) plus TKI（e.g. sunitinib, pezopanib，dosage based on guidelines or instructions)” NCT06427057 ↗ “Study drug: Sunitinib peroral tablet 50 mg once a day for 4 weeks, hereafter pause for 2 weeks (4/2 schedule or 2/1 schedule).” NCT04644432 ↗ “Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol” NCT02960906 ↗ “Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.” NCT01210053 ↗ “Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.” NCT00471328 ↗ “Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC)” PMID 36749752 ↗ Feb 2023 “In total, 23 patients were enrolled and were treated with a starting daily, oral dose of 37.5 mg sunitinib.” PMID 26671977 ↗ Dec 2015 “The purpose of this study is to test SU011248 (sunitinib) in combination with paclitaxel/carboplatin.” NCT00511849 ↗ “Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers.” NCT01621568 ↗ “Sunitinib is an approved treatment for metastatic renal cell carcinoma (mRCC).” PMID 27713637 ↗ Sep 2016 “subcutaneous low dose IL-2, interferon-α or sunitinib” NCT00397345 ↗ “Sunitinib 37.5 mg by mouth every day.” NCT00905021 ↗ “Streptozocin, Sunitinib, Tamoxifen” NCT02788201 ↗ “Sunitinib, Sorafenib or Pazopanib” NCT01731158 ↗ “Sorafenib Sunitinib Temsirolimus” NCT02551718 ↗ “sunitinib malate (sunitinib)” NCT01664182 ↗ “SU011248 (Sunitinib)” NCT00371553 ↗ “SU011248 (sunitinib)” NCT00137423 ↗ “Drug: Sunitinib” NCT03091192 ↗ “sunitinib” NCT01158222 ↗ “Sunitinib” NCT02142036 ↗ |
| Known as | GB-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03249740 ↗ |
| Known as | NSC 736511 | “Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study” NCT00453154 ↗1“A Phase II Evaluation of Sunitinib Malate (Sutent®, SU11248, NCI-Supplied Agent , NSC # 736511) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus” NCT00378911 ↗ |
| Known as | NSC-750690 | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | PHA-290940AD | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | SU 11248 | “Sunitinib (SU 11248) is a small molecule with good oral bioavailability that inhibits multiple receptor tyrosine kinases (RTKs) expressed on diverse tumour cells: VEGFR, PDGFR,...” NCT01100177 ↗6“A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast” NCT00482755 ↗ “An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma” NCT01216657 ↗ “SUTENT (SUNITINIB, SU11248) is a potent multi-target inhibitor of VEGFR1-3, PDGFR-α/β, FLT3, c-KIT, RET and CSF-1R.” NCT00535379 ↗ “A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain” NCT00462982 ↗ |
| Known as | SU-010398 | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | SU-011248 L-MALATE SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | SU011248 | “A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED...” NCT01525550 ↗37“The Influence of Genotype/Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib (Sutent, SU011248) in Patient With Imatinib Resistant...” NCT01743300 ↗ “A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer...” NCT00457392 ↗ “SU011248 is an orally administered inhibitor of the vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, FLT-3 and c-KIT.” NCT00299741 ↗ “A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer” NCT00338884 ↗ “Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors” NCT00428597 ↗ “Sunitinib (SU011248) was administered orally daily for 4 weeks followed by a 2-week rest at a starting dose of 50 mg” NCT00226811 ↗ “Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma” NCT00589784 ↗ “Sunitinib Malate (SU011248)” NCT00793871 ↗ “Sunitinib Malate (SU011248)” NCT00706706 ↗ “Sunitinib (SU011248)” NCT00550810 ↗ “SU-011248 capsule” NCT00254540 ↗ |
| Known as | SU011248, Sutent | “SU011248, Sutent” NCT00247676 ↗ |
| Known as | SU011248-Sutent-Sunitinib | “SU011248-Sutent-Sunitinib” NCT00611728 ↗ |
| Known as | SU11248 is also known as Sutent | “SU11248 is also known as Sutent” NCT00304200 ↗ |
| Known as | SUN | “Sunitinib (SUN)-induced hypoxia within the tumor could promote the activation of the prodrug evofosfamide (EVO), locally releasing the cytotoxic DNA alkylator...” PMID 34190375 ↗ Jul 20211“Our main comparator was sunitinib (SUN).” PMID 37146227 ↗ May 2023 |
| Known as | Sunitinib accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | Sunitinib l-malate | ChEMBL registry synonym — accepted as the source's own label CHEMBL535 ↗ |
| Known as | sunitinib malate | “A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED...” NCT01525550 ↗55“Sunitinib malate is an orally administered small molecule that inhibits the tyrosine kinase enzymatic activities of the receptors for VEGF and PDGF, and also blocks signalling...” NCT01731925 ↗ “To assess the efficacy (objective response rate) of sunitinib (sunitinib malate) given orally daily for 4 out of every 6 weeks in patients with unresectable, locally advanced...” NCT00389974 ↗ “sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or...” NCT00375674 ↗ “To evaluate the anti-tumor activity of SU11248 (sunitinib malate), a highly potent, selective tyrosine kinases inhibitor, in patients with persistent or recurrent clear cell...” NCT00979992 ↗ “This is a phase II study to evaluate the effectiveness of study drug sunitinib malate in patients with recurrent and/or metastatic adenoid cystic carcinomas of the salivary gland.” NCT00886132 ↗ “This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer.” NCT00411151 ↗ “Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings.” NCT00730353 ↗ “RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT01024205 ↗ “OBJECTIVES: Primary * Demonstrate the antitumor activity of continuous sunitinib malate treatment in patients with unresectable hepatocellular carcinoma.” NCT00514228 ↗ “Sunitinib malate capsule 50mg administered orally, once daily in 28-day cycle(14 days on treatment from Day 1-14, 14 days off treatment from day 15-28).” NCT04523272 ↗ “Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00521092 ↗ “Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT01089088 ↗ “Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.” NCT00891878 ↗ “Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.” NCT01164228 ↗ “Determine the maximum tolerated dose (MTD) and recommended phase II dose of sunitinib malate in pediatric patients with refractory solid tumors.” NCT00387920 ↗ “This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere).” NCT00712504 ↗ “Patients receive bevacizumab IV over 30-90 minutes on days 1, 15, and 29 and oral sunitinib malate (SU11248) once daily on days 1-28.” NCT00357318 ↗ “Determine the feasibility of neoadjuvant sunitinib malate in patients with newly diagnosed, resectable stage II-IIIA breast cancer.” NCT00482755 ↗ “Evaluate the response of sunitinib (sunitinib malate) per Response Evaluation Criteria in Solid Tumors (RECIST) criteria” NCT00519896 ↗ “Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle.” NCT00434109 ↗ “Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)” NCT00495625 ↗ “sunitinib (sunitinib malate) (Sutent), an oral tyrosine kinase inhibitor with antiangiogenic activity” NCT00813423 ↗ “Sunitinib Malate 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.” NCT00912912 ↗ “Drug: sunitinib malate Will be administered at 50 mg daily, 4 weeks on, 2 weeks off” NCT00425386 ↗ “Sunitinib malate is a small multi-targeted tyrosine kinase inhibitor” PMID 27109549 ↗ Apr 2016 “Patients receive sunitinib malate orally once daily on days 1-28.” NCT00392496 ↗ “Patients receive oral sunitinib malate once daily on days 1-28.” NCT00392444 ↗ “Patients receive oral sunitinib malate once daily on days 1-28.” NCT00459979 ↗ “Patients receive oral sunitinib malate once daily for 8 weeks.” NCT00747305 ↗ “Patients receive oral sunitinib malate once daily for 4 weeks.” NCT00853125 ↗ “Sunitinib malate (37.5 mg) oral daily for days 1-14” NCT00859339 ↗ “SU011248 (sunitinib malate, SUTENT)” NCT00137436 ↗ “sunitinib (sunitinib malate)” NCT01740154 ↗ “sunitinib (sunitinib malate)” NCT01243359 ↗ “sunitinib malate (sunitinib)” NCT01664182 ↗ “Sunitinib Malate (SU011248)” NCT00400569 ↗ “Sunitinib Malate (SU011248)” NCT00706706 ↗ “Sunitinib Malate (SU011248)” NCT00329043 ↗ “Sunitinib Malate (SU011248)” NCT00793871 ↗ “Sunitinib Malate (Sutent)” NCT00480935 ↗ “Drug: Sunitinib Malate” NCT03463460 ↗ “Drug: sunitinib malate” NCT00699374 ↗ “Drug: Sunitinib Malate” NCT03909724 ↗ “Drug: Sunitinib Malate” NCT00478426 ↗ “Drug: Sunitinib malate” NCT00402415 ↗ |
| Known as | Sunitinib malate (suntinib; SU11248, SU011248, Sutent) | “Sunitinib malate (suntinib; SU11248, SU011248, Sutent®)” NCT00843037 ↗ |
| Known as | Sunitinib maleate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00891475 ↗ |
| Known as | Sunitinib, NSC 736511, Sutent | “Sunitinib, NSC 736511, Sutent” NCT00961571 ↗ |
| Known as | SUO11248 | “This study is a randomized, blinded, placebo-controlled study evaluating the drug, SUO11248 (SUTENT), for maintenance therapy in advanced urothelial cancer.” NCT00393796 ↗1“Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)” NCT00495625 ↗ |
| Known as | SUTENT | “Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor (TKI) with activity against the stem cell-factor receptor (KIT) and platelet-derived...” NCT02623127 ↗22“A Multicenter, Phase II, Randomized, Blinded, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Sutent With or Without Bevacizumab in First-Line Patients With...” NCT00491738 ↗ “Sunitinib (SUTENT) is a potent tyrosine kinase inhibitor, with double antiangiogenic and antitumor activity, targeting multiple receptors as VEGF-R, PDGF-R, KIT and FLT3.” NCT01215565 ↗ “The THYSU trial is a phase II trial of sunitinib (Sutent) in patients with locally advanced or metastatic anaplastic, differentiated or medullary thyroid carcinoma.” NCT00510640 ↗ “sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year” NCT01164202 ↗ “This study is determining the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel (Taxotere).” NCT00712504 ↗ “Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors” NCT00428597 ↗ “A Phase II Study of SUNITINIB MALATE (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer” NCT00524316 ↗ “the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously” NCT00748358 ↗ “Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas” NCT01402817 ↗ “sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.” NCT00400114 ↗ “Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles.” NCT00930345 ↗ “SU011248 (Sutent) in Combination With Irinotecan and Cetuximab” NCT00361244 ↗ “Bezuclastinib in combination with sunitinib (sutent)” NCT06208748 ↗ “The marketing name of this drug is "Sutent".” NCT02074878 ↗ “Sunitinib (Sutent) 37.5 mg in schedule 2/1” NCT00291577 ↗ “SU011248 (sunitinib malate, SUTENT)” NCT00137436 ↗ “sunitinib (Sutent)” NCT00904657 ↗ “Sunitinib (Sutent)” NCT00788060 ↗ “Sutent (sunitinib)” NCT00631618 ↗ “Sutent (sunitinib)” NCT00923117 ↗ |
| Known as | SUTENT (REGISTERED) | “A SINGLE-ARM OPEN-LABEL INTERNATIONAL MULTI-CENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB MALATE (SU011248, SUTENT (REGISTERED)) IN PATIENTS WITH PROGRESSIVE ADVANCED...” NCT01525550 ↗ |
| Known as | SUTENT (Sunitinib) | “SUTENT (Sunitinib)” NCT01054911 ↗1“Sutent, sunitinib” NCT00471276 ↗ |
| Known as | Sutent(R) | “Sunitinib (Sutent(R)) is approved by the Food and Drug Administration (FDA) for the treatment of advanced renal cell (kidney) cancer and gastrointestinal stromal tumors.” NCT00402415 ↗ |
| Action | Inhibit | “Platelet-derived growth factor receptor alpha inhibitor” CHEMBL535 ↗6“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL535 ↗ “Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL535 ↗ “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL535 ↗ “Macrophage colony stimulating factor receptor inhibitor” CHEMBL535 ↗ “Platelet-derived growth factor receptor beta inhibitor” CHEMBL535 ↗ “sunitinib, a multitargeted tyrosine kinase inhibitor” PMID 17046465 ↗ Oct 2006 |
| Modality | Small molecule | “an Oral Multi-Targeted Tyrosine Kinase Inhibitor” NCT00392496 ↗ |
| Route | Oral | “by oral capsule” NCT00056693 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL535 ↗ |
| Target | FLT1 | “Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL535 ↗ |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL535 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL535 ↗ |
| Target | KIT | “SU011248 is an orally administered inhibitor of the vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor (PDGF) receptor, FLT-3 and c-KIT.” NCT00299741 ↗ |
| Target | PDGFRA | “Platelet-derived growth factor receptor alpha inhibitor” CHEMBL535 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL535 ↗ |